Key Highlights

  • DexCom shares fell 2.02% at last closing to $87.90 per share.
  • Revenue of roughly $1.31 billion rose around 13% on a reported basis and around 12% organically, with US Revenue up around 11% and international up around 19%.
  • The company raised its full-year 2026 revenue guidance to imply growth in the low double digits and lifted its Margin targets.
  • Recent developments included positive randomized-trial data supporting continuous glucose monitoring in type 2 diabetes and a redesigned biosensor app with AI-driven insights.

DexCom, Inc. (NASDAQ:DXCM) shares fell at last closing. DexCom makes continuous glucose monitoring systems for diabetes, along with an over-the-counter biosensor.

The most recent quarter delivered double-digit growth, expanding margins, raised guidance, and positive clinical data, with the honest caveats being a premium valuation and competition from a large rival rather than any weakness in the fundamentals.

Latest Developments

In its most recent quarter, DexCom reported revenue of roughly $1.31 billion, up around 13% on a reported basis and around 12% organically, with US revenue up around 11% and international up around 19%. GAAP gross margin was in the low 60s percent, GAAP Net Income was around $249 million with Earnings Per Share of around $0.64, and non-GAAP earnings per share were about $0.70. The company raised its full-year 2026 revenue guidance to imply growth in the low double digits and lifted its margin targets. Recent developments included positive randomized-trial data supporting continuous glucose monitoring in type 2 diabetes and a redesigned biosensor app with artificial-intelligence-driven insights.

Financial and Business Position

The financial position is strong, with double-digit revenue growth, expanding gross margin, and raised guidance, supported by strong international growth and positive clinical data reinforcing the case for continuous glucose monitoring in type 2 diabetes. The main considerations are the premium valuation typical of a leading medical-technology name and competition from a large rival in the glucose-monitoring market.

Stock-Market Context

DexCom shares closed at $87.90 at last closing, down 2.02%. The stock has traded near its 52-week highs on a bullish re-rating following recent beat-and-raise quarters, and analyst tone has been genuinely bullish, citing the combination of double-digit growth and margin expansion.

What Investors Should Watch

Investors should watch revenue growth in the US and internationally, gross-margin expansion against the raised targets, the uptake of the over-the-counter biosensor, and clinical data supporting broader continuous-glucose-monitoring adoption, along with competition from the large rival and the premium valuation.